Association between dose-volume parameters and acute bone marrow suppression in rectal cancer patients treated with concurrent chemoradiotherapy

Nan Li; Xue Liu; Fushan Zhai; Bing Liu; Xiaohui Cao; Shuyan Li; Minxian Zhang; Ming Liu

doi:10.18632/oncotarget.21646

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Association between dose-volume parameters and acute bone marrow suppression in rectal cancer patients treated with concurrent chemoradiotherapy

Nan Li, Xue Liu, Fushan Zhai, Bing Liu, Xiaohui Cao, Shuyan Li, Minxian Zhang and Ming Liu _

PDF | HTML | How to cite

Oncotarget. 2017; 8:92904-92913. https://doi.org/10.18632/oncotarget.21646

Metrics: PDF 1267 views | HTML 2159 views | ?

Abstract

Nan Li1, Xue Liu1, Fushan Zhai1, Bing Liu1, Xiaohui Cao1, Shuyan Li1, Minxian Zhang1 and Ming Liu1

1Department of Radiotherapy and Oncology, Third Hospital of Hebei Medical University, Shijiazhuang, China

Correspondence to:

Ming Liu, email: [email protected]

Keywords: concurrent chemoradiotherapy, acute bone marrow suppression, dose-volume parameters, rectal cancer, pelvic bone marrow

Received: July 13, 2017 Accepted: August 27, 2017 Published: October 06, 2017

ABSTRACT

Concurrent chemoradiotherapy is one of the main treatments for rectal cancer. Bone marrow suppression is one of the critical factors that affect the progress of radiotherapy. We aimed to explore the association of incidence of acute bone marrow suppression with dose-volume parameters of pelvic bone marrow among rectal cancer patients with concurrent chemoradiotherapy. We retrospectively analyzed 50 rectal cancer patients for multivariate logistic regression analyses. Three subdomains of pelvic bone marrow (PBM), bilateral ilium (IBM), lower pelvis (LPBM), and lumbosacral spine (LSBM) were assigned. The radiation dose-volume parameters from the three subdomains and the whole pelvis were evaluated. Compared to Grade 0-1 leukopenia patients, ≥Grade 2 leukopenia patients exhibited significantly higher levels of IBM V₂₀, V₂₅, V₃₅, mean dose (Dmean), LPBM V₂₀, V₂₅, V₃₀, LSBM V₁₅, PBM V₁₅, V₂₀, and PTV. The PBM V₂₀ of ≥Grade 2 neutropenia patients was significantly higher than that of Grade 0-1 neutropenia patients. Multivariate analysis have demonstrated that IBM V₂₀ and LSBM V₁₅ were the independent factors affecting ≥ Grade 2 leukopenia. There is a correlation between low dose-volume parameters with acute bone marrow suppression. IBM V₂₀, LSBM V₁₅ and PBM V₂₀ can be employed as the predictors of acute bone marrow suppression.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 21646

Publication Alerts

Research Papers:

Association between dose-volume parameters and acute bone marrow suppression in rectal cancer patients treated with concurrent chemoradiotherapy

Abstract